MUJN Diagnostics – a subsidiary of PanGenomic Health – is partnering with Portland, Oregon-based medical diagnostic device company Hemex Health to develop a diagnostics system, which can be used to support patients being treated with alternative therapies for brain health.
This system will objectively track the efficacy of a patient’s treatment programme. As part of this engagement, MUJN Diagnostics will develop proprietary brain biomarker diagnostic panels, and Hemex Health will enhance its Gazelle point-of-care platform to analyse these tests. In March 2023, MUJN Diagnostics and Hemex Health initiated the diagnostic cartridge design phase of the engagement.
“The relationship between MUJN Diagnostics and Hemex Health is expected to help usher in a new platform for integrated healthcare professionals using new brain health therapies to more effectively monitor and treat their patients,” said Vincent Lum, CEO and President of MUJN Diagnostics and Co-Founder of PanGenomic Health. “New promising alternative therapies for a variety of brain and mental health conditions and disorders, such as the use of psychedelics as a part of a structured treatment program, need objective data for clinicians and their patients to track and quantify the efficacy of their treatment.”
Patti White, CEO of Hemex Health, said: “We designed our Gazelle technology to provide advanced capabilities at point of care, and we’re excited to have Gazelle provide the analysis of these new biomarkers.”
Hemex Health’s diagnostic system expands the potential of diagnostics for emerging diseases. Gazelle technology was developed in collaboration with Case Western Reserve University. More information can be found by going to www.hemexhealth.com.
